Skip to main content

Main menu

  • Home
  • Content
    • Current Issue
    • Past Issues
    • Accepted Articles
    • Email Alerts
    • RSS
    • Terms of Use
  • About PDA JPST
    • JPST Editors and Editorial Board
    • About/Vision/Mission
    • Paper of the Year
  • Author & Reviewer Resources
    • Author Resources / Submit
    • Reviewer Resources
  • JPST Access and Subscriptions
    • PDA Members
    • Institutional Subscriptions
    • Nonmember Access
  • Support
    • Join PDA
    • Contact
    • Feedback
    • Advertising
    • CiteTrack
  • .
    • Visit PDA
    • PDA Letter
    • Technical Reports
    • news uPDATe
    • Bookstore

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
PDA Journal of Pharmaceutical Science and Technology
  • .
    • Visit PDA
    • PDA Letter
    • Technical Reports
    • news uPDATe
    • Bookstore
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
PDA Journal of Pharmaceutical Science and Technology

Advanced Search

  • Home
  • Content
    • Current Issue
    • Past Issues
    • Accepted Articles
    • Email Alerts
    • RSS
    • Terms of Use
  • About PDA JPST
    • JPST Editors and Editorial Board
    • About/Vision/Mission
    • Paper of the Year
  • Author & Reviewer Resources
    • Author Resources / Submit
    • Reviewer Resources
  • JPST Access and Subscriptions
    • PDA Members
    • Institutional Subscriptions
    • Nonmember Access
  • Support
    • Join PDA
    • Contact
    • Feedback
    • Advertising
    • CiteTrack
  • Follow pda on Twitter
  • Visit PDA on LinkedIn
  • Visit pda on Facebook
Article CommentaryCOMMENTARY

Container–Content Compatibility Studies: A Pharmaceutical Team's Integrated Approach

Alda Laschi, Natacha Sehnal, Antoine Alarcon, Beatrice Barcelo, François Caire-Maurisier, Myriam Delaire, Marc Feuilloley, Stéphanie Genot, Catherine Lacaze, Luc Pisarik and Christophe Smati
PDA Journal of Pharmaceutical Science and Technology July 2009, 63 (4) 285-293;
Alda Laschi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: Alda.Laschi@sanofipasteur.com
Natacha Sehnal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Antoine Alarcon
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Beatrice Barcelo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
François Caire-Maurisier
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Myriam Delaire
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marc Feuilloley
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stéphanie Genot
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Catherine Lacaze
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Luc Pisarik
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christophe Smati
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • References
  • Info & Metrics
  • PDF
Loading

Abstract

Container–content compatibility studies are required as part of the submission of a new product market authorization file or for a change relating to the primary product-contact packaging. Many regulatory publications and guidances are available in the USA, Europe, and Japan. However these publications and guidances are not sufficiently precise enough to allow for consistent interpretation and implementation of the technical requirements.

A working group has been formed by the French Society of Pharmaceutical Science and Technology (SFSTP) in order to propose guidance for container–content interaction studies that meet both European and US requirements, and allows consistent and standardized information to be presented by the industry to the regulators.

When a pharmaceutical drug product remains in prolonged contact with a material, the two critical points to consider are the drug product's quality and safety. A pharmaceutical evaluation of the container–content relationship should be done based on the knowledge of the contact material (e.g., type, physicochemical properties), its manufacturing processes (e.g., the type of sterilization that could potentially alter the interactions), and the formulation components involved in contact with this material (e.g., physicochemical properties, pharmaceutical presentation, route of administration). Quality is evaluated using the stability study performed on the product. Safety is partially evaluated with the stability study and is analyzed in conjunction with toxicity testing, specifically with cytotoxicity testing. The toxicity aspect is the key point of the container–content compatibility study and of patient safety.

Migration tests are conducted when an interaction is suspected, or found based on previous results, to identify the component responsible for this interaction and to help select a new material if needed. Therefore, such tests are perhaps not the best ones to use for the purpose of safety evaluation. Consequently, a decision tree based mainly on the toxicity aspect is proposed in order to support the pharmaceutical companies' container–content interaction approach and filing.

  • Extractable
  • Leachable
  • Container
  • In process material
  • Safety
  • Toxicological evaluation
  • Decision tree
  • SCT
  • QT

Footnotes

  • © PDA, Inc. 2009
View Full Text

PDA members receive access to all articles published in the current year and previous volume year. Institutional subscribers received access to all content. Log in below to receive access to this article if you are either of these.  

If you are neither or you are a PDA member trying to access an article outside of your membership license, then you must purchase access to this article (below). If you do not have a username or password for JPST, you will be required to create an account prior to purchasing. 

Full issue PDFs are for PDA members only.

Note to pda.org users

The PDA and PDA bookstore websites (www.pda.org and www.pda.org/bookstore) are separate websites from the PDA JPST website. When you first join PDA, your initial UserID and Password are sent to HighWirePress to create your PDA JPST account. Subsequent UserrID and Password changes required at the PDA websites will not pass on to PDA JPST and vice versa. If you forget your PDA JPST UserID and/or Password, you can request help to retrieve UserID and reset Password below.

Log in using your username and password

Forgot your user name or password?

Log in through your institution

You may be able to gain access using your login credentials for your institution. Contact your library if you do not have a username and password.
If your organization uses OpenAthens, you can log in using your OpenAthens username and password. To check if your institution is supported, please see this list. Contact your library for more details.

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.

patientACCESS

patientACCESS - Patients desiring access to articles

Full issue PDFs are for PDA members only. You can join PDA at www.pda.org. 

PreviousNext
Back to top

In This Issue

PDA Journal of Pharmaceutical Science and Technology
Vol. 63, Issue 4
July/August 2009
  • Table of Contents
  • Index by Author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on PDA Journal of Pharmaceutical Science and Technology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Container–Content Compatibility Studies: A Pharmaceutical Team's Integrated Approach
(Your Name) has sent you a message from PDA Journal of Pharmaceutical Science and Technology
(Your Name) thought you would like to see the PDA Journal of Pharmaceutical Science and Technology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
3 + 3 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Container–Content Compatibility Studies: A Pharmaceutical Team's Integrated Approach
Alda Laschi, Natacha Sehnal, Antoine Alarcon, Beatrice Barcelo, François Caire-Maurisier, Myriam Delaire, Marc Feuilloley, Stéphanie Genot, Catherine Lacaze, Luc Pisarik, Christophe Smati
PDA Journal of Pharmaceutical Science and Technology Jul 2009, 63 (4) 285-293;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Container–Content Compatibility Studies: A Pharmaceutical Team's Integrated Approach
Alda Laschi, Natacha Sehnal, Antoine Alarcon, Beatrice Barcelo, François Caire-Maurisier, Myriam Delaire, Marc Feuilloley, Stéphanie Genot, Catherine Lacaze, Luc Pisarik, Christophe Smati
PDA Journal of Pharmaceutical Science and Technology Jul 2009, 63 (4) 285-293;
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Regulatory Publications
    • Migration Phenomena Evalutation
    • Toxicological Aspects
    • Decision Trees
    • Extractables Study
    • Leachables Study
    • Conclusion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • References
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Perspectives on the PQRI Extractables and Leachables "Safety Thresholds and Best Practices" Recommendations for Inhalation Drug Products
  • Google Scholar

More in this TOC Section

  • Chemical and Process Parameters Influencing Gelling during Pharmaceutical Wet Media Milling
  • Challenges Encountered in the Implementation of Bio-Fluorescent Particle Counting Systems as a Routine Microbial Monitoring Tool
  • Parametric Release of Moist Heat Sterilized Products: History and Current State
Show more Commentary

Similar Articles

Readers

  • About
  • Table of Content Alerts/Other Alerts
  • Subscriptions
  • Terms of Use
  • Contact Editors

Author/Reviewer Information

  • Author Resources
  • Submit Manuscript
  • Reviewers
  • Contact Editors

Parenteral Drug Association, Inc.

  • About
  • Advertising/Sponsorships
  • Events
  • PDA Bookstore
  • Press Releases

© 2023 PDA Journal of Pharmaceutical Science and Technology ISSN: 1079-7440

Powered by HighWire